Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/28/2025 | Mkt Perform | William Blair | |
| 12/10/2024 | $40.00 → $5.00 | Overweight → Underweight | Morgan Stanley |
| 12/9/2024 | $42.00 → $7.00 | Buy → Hold | Jefferies |
| 12/9/2024 | $45.00 → $7.00 | Buy → Neutral | Citigroup |
| 10/21/2024 | $45.00 | Buy | Citigroup |
| 10/21/2024 | $42.00 | Buy | Jefferies |
| 10/21/2024 | $40.00 | Overweight | Morgan Stanley |
4/A - BioAge Labs, Inc. (0001709941) (Issuer)
4 - BioAge Labs, Inc. (0001709941) (Issuer)
4 - BioAge Labs, Inc. (0001709941) (Issuer)
SCHEDULE 13G - BioAge Labs, Inc. (0001709941) (Subject)
SCHEDULE 13G/A - BioAge Labs, Inc. (0001709941) (Subject)
10-Q - BioAge Labs, Inc. (0001709941) (Filer)
4 - BioAge Labs, Inc. (0001709941) (Issuer)
4 - BioAge Labs, Inc. (0001709941) (Issuer)
4 - BioAge Labs, Inc. (0001709941) (Issuer)
William Blair initiated coverage of BioAge Labs with a rating of Mkt Perform
Morgan Stanley downgraded BioAge Labs from Overweight to Underweight and set a new price target of $5.00 from $40.00 previously
Jefferies downgraded BioAge Labs from Buy to Hold and set a new price target of $7.00 from $42.00 previously
EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ:BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences: Citi's 2025 Biopharma Back to School Conference (Boston, September 2–3, 2025): Kristen Fortney, PhD, CEO and co-founder, and Dov Goldstein, MD, CFO, are scheduled to participate in a fireside chat on Wednesday, September 3 at 3:15–3:55 PM EDT, and will participate in one-on-one meetings. To access the live webcast of the presentation, regi
First-in-human study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102, an orally available small molecule with potential best-in-class profile Initial development planned in obesity; BGE-102 demonstrated robust weight loss in preclinical models, both as monotherapy and in combination with GLP-1 receptor agonists Initial Phase 1 SAD data anticipated by end of 2025, with top-line readout of obesity study by end of 2026 EMERYVILLE, Calif., Aug. 15, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ:BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biolog
Oral NLRP3 inhibitor BGE-102 on track for Phase 1 initiation in 2H 2025 with initial data by year-end Expanded APJ agonist pipeline through option agreement for novel antibody and advancement of proprietary oral small molecules Strengthened discovery platform through molecular profiling of 17,000+ samples from leading European HUNT Biobank EMERYVILLE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today provided business updates and reported its second quarter 2025 financial results. "In
SC 13G - BioAge Labs, Inc. (0001709941) (Subject)
SC 13G - BioAge Labs, Inc. (0001709941) (Subject)
SC 13D - BioAge Labs, Inc. (0001709941) (Subject)